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Abstract
Rivastigmine has been shown to improve cognition in HIV+ patients with
minor neurocognitive disorders; however, the mechanisms underlying such ben-
eficial effect are currently unknown. To assess whether rivastigmine therapy is
associated with decreased brain inflammation and damage, we performed T1/
T2* relaxometry and magnetization transfer imaging in 17 aviremic HIV+
patients with minor neurocognitive disorders enrolled on a crossed over ran-
domized rivastigmine trial. Rivastigmine therapy was associated with changes in
MRI metrics indicating a decrease in brain water content (i.e., edema reabsorp-
tion) and/or reduced demyelination/axonal damage. Furthermore, MRI changes
correlated with cognitive improvement on rivastigmine therapy.
Introduction
Rivastigmine is a dual acetyl- and butyrylcholinesterase
inhibitor (ChEI) that is commonly used to alleviate
cognitive deficits in Alzheimer’s disease (AD).1 Recently,
we have provided first evidence that rivastigmine
improves some cognitive deficits in HIV patients with
mild neurocognitive disorder (MND).2 In AD patients,
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rivastigmine achieves its positive effects on cognition
through multiple mechanisms encompassing enhanced
cholinergic neurotransmission and improved clearance of
amyloid plaques.3 The putative beneficial effect of
rivastigmine in HIV+ patients may be due to a decrease
in brain acetylcholine levels, related to a deficit in choline
acetyltransferase.4 Yet, in HIV patients, rivastigmine may
also improve cognitive outcome by reducing brain
inflammation and damage. Indeed, rivastigmine has been
reported to markedly temper microglia activation,
demyelination, and axonal damage in experimental
autoimmune encephalomyelitis, leading to improved spa-
tial memory deficits.5 Also, in a cellular model of HIV-
associated dementia, the adjunction of galantamine,
another ChEI, resulted in the inhibition of microglial acti-
vation induced by HIV-1 proteins.6 Moreover, the activa-
tion of the cholinergic anti-inflammatory system by
nicotine was shown to attenuate neuroinflammation via
suppression of Th1 and Th17 responses.7
In this study, we used multiparametric MRI (mpMRI)
to investigate the effect of rivastigmine on brain inflam-
mation and damage in MND HIV patients who partici-
pated to a blinded randomized crossed over trial to assess
rivastigmine efficacy and safety.2 Multiparametric quanti-
tative MRI represents a sensitive approach to study
inflammatory and degenerative brain changes.8 In fact,
quantitative MRI metrics such as T1 and T2* relaxometry
and semiquantitative MRI parameters like magnetization
transfer ratio (MTR) may provide complementary infor-
mation regarding the brain tissue structure and its com-
ponents: T1 relaxation times are sensitive to the tissue
organization of micro- and macromolecules, and to a les-
ser extent to iron content;9 T2* relaxation times exhibit
high sensitivity to quantify paramagnetic substances like
iron and provide additional information concerning the
presence of free and bound water molecules (i.e., myelin
water9). On the other hand, MTR is highly sensitive to
the presence and extent of macromolecules such as mye-
lin, cellular membranes components, etc.9
Therefore, the combination of T1/T2 relaxometry and
MTR may help disentangling whether brain structural
changes underlie the benefits of rivastigmine in HIV patients.
Methods
Subjects’ population
We studied 17 patients with HIV infection, undetectable
viremia, and MND, who were enrolled in a blinded cross-
over randomized study to assess efficacy and safety of
rivastigmine for the treatment of MND.2 MND was diag-
nosed according to Frascati criteria10 using an extensive
neuropsychological and neuropsychiatric battery of tests.2
Exclusion criteria were previous brain opportunistic infec-
tion, any other opportunistic infection in the last year,
active drug consumption, and major depression according
to DSM-IV criteria. No patient developed psychiatric
(e.g., psychosis) or neurological conditions (e.g., stroke),
which could have interfered with neuropsychological or
MRI evaluation. Patients clinical characteristics are sum-
marized in Table S1.
Patients were randomly assigned to two arms receiving
either rivastigmine or placebo for 20 weeks, followed by a
6 weeks washout, and then by 20 weeks where treatments
were inversed between the two arms (see Simioni et al.2
for details).
All patients had undetectable HIV-RNA in the plasma
(defined as <20 copies/mL for more than 3 months) and
in the cerebrospinal fluid (<200 copies/L) at study entry;
at study end, plasmatic HIV-RNA was detected in one
patient (147 copies/mL).
Brain MRI scans were performed before the treatment
was started (time point 0, TP0), at 20 weeks (TP1), and
at 46 weeks (TP2) (Fig. 1). Five patients could not com-
plete the MRI follow-up and were therefore excluded
from the analysis.
A neuropsychological evaluation was also performed at
TP0, TP1, and TP2 for all subjects. Neuropsychological
tests explored cognitive domains which are usually
impaired in MND patients. They included reaction time
and rapid visual information processing and spatial work-
ing memory (strategy and error component) from the
Cambridge Neuropsychological Test Automated Battery
(CANTAB), Trail Making Test Parts A and B, Wechsler
Adult Intelligence Scale-III Symbol Digit Test, CANTAB,
Digit Spans Backward/Forward, and Stockings of Cam-
bridge (see 2 for details).
Magnetic Resonance Imaging
All MRI scans were performed on a 3T Magnetom Trio
(a Tim System, Siemens, Erlangen, Germany) equipped
with a 32-channel head coil.
The study protocol consisted a high-resolution, T1-
weighted magnetization prepared rapid gradient echo
Figure 1. Study design and MRI time points (TP).
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(MPRAGE) acquisition for anatomical reference; an
MP2RAGE acquisition with the same voxel and matrix
size to obtain T1 relaxation maps;11 and a multiple echo
Fast Low Angle SHot (FLASH) with and without magne-
tization transfer preparation. The signals acquired with
(MT) and without (M0) magnetization saturation pulse
were used to compute magnetization transfer ratio
(MTR) maps as reported previously.8,12 T2 star maps
were calculated using a monoexponential fitting as per-
formed previously.8,12 Brain segmentation into gray and
white matter (GM and WM) was performed using Mor-
phobox13 (see Data S1) and segmentation quality was
visually inspected. Mean T1 rt, T2* rt, and MTR were
calculated in each ROI (WM and GM) at each time
point. The study was approved by the ethics committee
of the Centre Hospitalier Universitaire Vaudois (CHUV) in
Lausanne (Switzerland), and all subjects gave informed
written consent.
Statistical analysis
Analysis of variance of multiparametric brain MRI
data
To measure the effect of rivastigmine on brain microstruc-
tural properties, we computed for each subject the difference
in T1rt, T2* rt, and MTR between TP1 and TP0 and TP2
and TP1 in WM and GM. Subsequently, we performed a
multivariate analysis of variance (MANOVA) for each MR
contrast and each brain tissue. Treatment and sequence of
treatment (Arm1, Arm2) were considered as fixed effects.
Bonferroni correction for multiple comparison was applied
(6 MANOVA; 2 regions of interest, that is, WM and GM;
and 3 MR parameters, that is, T1 rt, T2*rt, and MTR).
Our null hypothesis was that there is no difference in
parametric MRI between patients treated with rivastig-
mine and patients who received placebo.
Figure 2. (A) Boxplot with superimposed dotplot showing significant differences (P < 0.01 and corrected-P < 0.05) obtained using crossed
MANOVA between rivastigmine-treated and placebo-treated patients for T2* rt in WM and MTR in WM and GM. Untreated patients in the two
arms are shown in light red, treated patients in light blue. (B) Summary plot showing significant differences (P < 0.01 and corrected-P < 0.05) in
T2* rt in GM and MTR in GM and WM in patients treated with rivastigmine (light blue) and placebo (red).
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To investigate the relationship between changes in MRI
metrics and changes in cognition during rivastigmine
treatment, we used a generalized linear model (GLM) and
assessed whether a linear regression of the variation of
T2* and MTR in WM and MTR in GM predicted the
variation in the Trail Making Test, Part A (TMTA)
z-score (calculated using available normative data), which
is the score that improved on rivastigmine in the previous
pilot trial in MND patients.2
Results
Mean T2* rt in WM was significantly different between
patients treated with rivastigmine and those treated with
placebo (P = 0.004, P-corr = 0.02, degrees of freedom:
11, standard error: 0.69; Table S2). Patients treated with
rivastigmine showed a decrease in WM T2* rt over time,
while patients treated with placebo exhibited an increase
in mean T2* rt (Fig. 2).
Mean MTR in WM and GM was significantly different
between patients treated with rivastigmine and those trea-
ted with placebo (P = 0.006, P-corr = 0.04, degrees of
freedom: 11, standard error: 0.004 for both; Table S2).
Patients treated with rivastigmine showed an increase in
MTR in both WM and GM, while patients treated with
placebo exhibited a decrease in MTR (Fig. 2).
T1 rt did not show any significant difference in WM
and GM between subjects with and without treatment.
The GLM analysis showed that the difference between
MTR after rivastigmine treatment and before rivastigmine
treatment (delta MTR) significantly correlated with the
difference in TMTAZ after and before treatment (delta
TMTAZ; adjusted R2 = 0.4, P = 0.03; Fig. 3).
Discussion
Our study provides evidence that rivastigmine treatment
reduces brain damage in MND HIV patients. Also, we
show that changes in MRI metrics on rivastigmine were
correlated with clinical improvement.
A recent pilot study performed by our group showed
that rivastigmine treatment for 20 weeks leads to an
improvement in processing speed and executive function
in HIV subjects with minor neurocognitive disorder.2
Still, whether brain structural changes underlay cognitive
improvement on rivastigmine in HIV-infected patients is
currently unknown.
Rivastigmine has been previously reported to decrease
brain inflammation (i.e., microglia activation,5 also when
triggered by HIV proteins6) and brain damage (demyeli-
nation and axonal injury5) in animal models and cell cul-
tures. We hypothesized that the cognitive improvement
measured in the rivastigmine trial in HIV patients2 is
paralleled by reduced brain inflammation and reversible
damage to myelin and axons.
Multiparametric MRI provides sensitive biomarkers of
brain inflammation and degeneration in HIV-infected
patients. By combining T1 and T2* relaxometry with mag-
netization transfer imaging, we have shown that aviremic
HIV patients with MND exhibit increased and diffuse
brain inflammation and degeneration compared to avire-
mic HIV patients without MND and to healthy subjects.12
In this pilot study, we applied exactly the same mpMRI
approach as described in Granziera et al.12 to assess the
effect of rivastigmine on brain inflammation and damage.
The concomitant decrease in MTR and T2* rt observed
in patients treated with rivastigmine strongly suggests an
increase in macromolecules (i.e., myelin or axons) and/or
a decrease in free water (i.e., edema reabsorption that
may induce an increase in MTR).
In fact, MTR parameter quantifies the interaction
between free protons and immobilized protons bound to
macromolecules and an increase in MTR has been linked
to an increase in myelination/axons14–16 or decrease in
water content.17–19 On the other hand, T2* relaxation
times reflect the loss of transverse magnetization due to T2
relaxation; therefore, a decrease in T2* relaxation times
may be provoked by an increase in macromolecular com-
pounds such as myelin.20,21 Interestingly, changes in brain
Figure 3. Correlation plot showing the positive relationship between
changes in the Trail Making Test A (TMTA) – normalized using
available normative data in TMTA z-score (TMTAZ) – and changes in
MTR after treatment. Changes in TMTAZ and MTR were calculated as
the difference between TMTAZ and MTR after rivastigmine treatment
and a TMTAZ and MTR at baseline.
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white matter MTR (i.e., increase in MTR) were signifi-
cantly related to the improvement in processing speed
(Trail Making Test Part A scores) on rivastigmine treat-
ment, suggesting that the improvement in cognitive func-
tion – reported in our previous pilot trial on rivastigmine
efficacy2 – may be mediated by a decrease in brain damage.
Our study suffers from some methodological limita-
tions. The first one is the small sample size of our cohort.
The second is that the MRI at TP1 was performed just
before the washout period, decreasing the sensitivity to
detect changes among time points. However, we tried to
take this latter effect into account by including the study
arm (i.e., sequence of treatment) as covariable in our
multivariate analysis.
In conclusion, we have shown that rivastigmine treat-
ment leads to a reduction in brain damage, alongside to
improved cognition in a group of HIV patients with
MND. Future studies should confirm and extend our cur-
rent findings in larger cohorts of patients and combining
mpMRI with biological assessments of inflammatory
markers in serum and cerebrospinal fluid before and after
rivastigmine treatment.
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